• Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, said it submitted a marketing authorization application for Scenesse (afamelanotide 16-mg implant) to the European Medicines Agency (EMA) covering use of the product as a prophylactic treatment in adults with erythropoietic protoporphyria. Scenesse received orphan drug designation in 2008 and will be reviewed under the EMA's centralized procedure.
Read More
LONDON – AstraZeneca plc said it will spend more of its annual $5 billion R&D budget with external partners as it announced it is once again taking the ax to the in-house R&D operations, in a third phase of restructuring that will see a further 2,200 job cuts added to the 5,300 R&D posts the company has cut since 2007. Read More
Even though ThromboGenics NV decided not to seek a priority review of its BLA for its symptomatic vitreomacular adhesion (VMA) drug ocriplasmin, the FDA decided to bestow one on the company anyway. The Leuven, Belgium-based firm now plans to withdraw its original BLA and to re-submit the file in April. The fast-track procedure should lead to a decision within six months. Read More
LONDON – Twenty-five European Union (EU) countries are to direct national funding for research in neurodegenerative disorders into a single, 10-year joint research plan which will see work in Alzheimer's and Parkinson's diseases, among others, coordinated across Europe.
Read More
Shares in AB Science SA surged 71.5 percent last week on news that its tyrosine kinase inhibitor masitinib strongly outperformed Sutent (sunitinib malate) in a Phase II head-to-head trial in 44 patients with Gleevec-resistant gastrointestinal stromal tumors.
Read More
LONDON – The discovery of a genetic variant that is associated with a higher risk of developing a particular type of stroke could one day lead to new treatments for that condition.
Read More
LONDON – Splitting its internal research effort into dozens of small teams, with each focusing on a particular disease or pathway, is on track to solve GlaxoSmithKline plc's productivity woes and push its return on investment in R&D to 14 percent.
Read More